Spots Global Cancer Trial Database for som230
Every month we try and update this database with for som230 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. | NCT01582061 | Cushing's Disea... | Pasireotide sub... | 18 Years - | Novartis | |
| Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease | NCT00434148 | Cushing's Disea... | Pasireotide | 18 Years - | Novartis | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | NCT01646684 | Castration Resi... | SOM230 | 18 Years - | Novartis | |
| Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs | NCT01590199 | Neuroendocrine ... | RAD001 SOM230 | 18 Years - | Novartis | |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | NCT01313559 | Castrate Resist... Chemotherapy Na... Prostate Cancer | Pasireotide Everolimus Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease | NCT01374906 | Cushing's Disea... | pasireotide LAR SOM230 LAR 30 m... SOM230 LAR 10 m... | 18 Years - | Novartis | |
| Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease | NCT02310269 | Cushings Diseas... | SOM230 | 18 Years - | RECORDATI GROUP | |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly | NCT01137682 | Acromegaly | Pasireotide octreotide LAR ... lanreotide ATG ... | 18 Years - | Novartis | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| SOM230 Ectopic ACTH-producing Tumors | NCT02780882 | Ectopic ACTH Sy... | Pasireotide | 18 Years - | Cedars-Sinai Medical Center | |
| Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess | NCT00994110 | Pancreatic Canc... | Pasireotide (SO... placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. | NCT01582061 | Cushing's Disea... | Pasireotide sub... | 18 Years - | Novartis | |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | NCT01639352 | Hepatocellular ... | SOM230 | 18 Years - | University of Miami |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
